|
Autolo Therapeutics PLC (AUTL) DCF Valoración
GB | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Autolus Therapeutics plc (AUTL) Bundle
Diseñada para la precisión, nuestra calculadora DCF (AUTL) le permite evaluar la valoración de Autolus Therapeutics PLC utilizando datos financieros del mundo real, ofreciendo una flexibilidad completa para modificar todos los parámetros clave para predicciones mejoradas.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.9 | .2 | 2.3 | 6.2 | 1.7 | 1.8 | 2.0 | 2.2 | 2.4 | 2.6 |
| Revenue Growth, % | 0 | -91.68 | 862.81 | 165.84 | -72.59 | 8.93 | 8.93 | 8.93 | 8.93 | 8.93 |
| EBITDA | -134.4 | -160.5 | -132.0 | -135.5 | -156.8 | -1.8 | -2.0 | -2.2 | -2.4 | -2.6 |
| EBITDA, % | -4621.63 | -66325.62 | -5665.49 | -2188.18 | -9232.63 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 4.6 | 5.7 | 8.5 | 7.4 | 6.6 | 1.8 | 2.0 | 2.2 | 2.4 | 2.6 |
| Depreciation, % | 158.56 | 2375.62 | 366.87 | 119.83 | 386.63 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -139.0 | -166.3 | -140.6 | -143.0 | -163.3 | -1.8 | -2.0 | -2.2 | -2.4 | -2.6 |
| EBIT, % | -4780.19 | -68701.24 | -6032.36 | -2308.01 | -9619.26 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 210.6 | 153.3 | 310.3 | 382.4 | 239.6 | 1.8 | 2.0 | 2.2 | 2.4 | 2.6 |
| Total Cash, percent | .0 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 30.5 | 29.7 | .1 | .2 | 1.0 | 1.0 | 1.1 | 1.2 | 1.3 | 1.4 |
| Account Receivables, % | 1049.66 | 12266.53 | 2.92 | 2.47 | 61.66 | 53.41 | 53.41 | 53.41 | 53.41 | 53.41 |
| Inventories | 7.8 | -29.7 | 10.1 | 14.2 | .0 | .7 | .8 | .9 | 1.0 | 1.0 |
| Inventories, % | 268.57 | -12266.53 | 434.51 | 228.54 | 0 | 40 | 40 | 40 | 40 | 40 |
| Accounts Payable | 1.1 | 2.3 | .4 | .5 | .1 | .6 | .7 | .7 | .8 | .9 |
| Accounts Payable, % | 36.97 | 935.12 | 18.5 | 8.57 | 6.07 | 34.02 | 34.02 | 34.02 | 34.02 | 34.02 |
| Capital Expenditure | -18.7 | -14.7 | -8.9 | -10.8 | -11.0 | -1.8 | -2.0 | -2.2 | -2.4 | -2.6 |
| Capital Expenditure, % | -641.95 | -6066.53 | -380.13 | -175.02 | -647 | -100 | -100 | -100 | -100 | -100 |
| Tax Rate, % | 0.009117 | 0.009117 | 0.009117 | 0.009117 | 0.009117 | 0.009117 | 0.009117 | 0.009117 | 0.009117 | 0.009117 |
| EBITAT | -123.8 | -142.1 | -120.3 | -122.8 | -163.3 | -1.7 | -1.8 | -2.0 | -2.1 | -2.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -175.2 | -111.5 | -132.7 | -130.3 | -154.9 | -1.8 | -1.9 | -2.1 | -2.2 | -2.5 |
| WACC, % | 21.4 | 21.04 | 21.05 | 21.08 | 22.5 | 21.42 | 21.42 | 21.42 | 21.42 | 21.42 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -5.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -2 | |||||||||
| Terminal Value | -13 | |||||||||
| Present Terminal Value | -5 | |||||||||
| Enterprise Value | -11 | |||||||||
| Net Debt | -187 | |||||||||
| Equity Value | 176 | |||||||||
| Diluted Shares Outstanding, MM | 174 | |||||||||
| Equity Value Per Share | 1.01 |
What You Will Get
- Real AUTL Financial Data: Pre-filled with Autolus Therapeutics' historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Autolus Therapeutics' intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive AUTL Data: Pre-loaded with Autolus Therapeutics' historical financials and future projections.
- Fully Customizable Inputs: Modify revenue growth, profit margins, discount rates, tax implications, and capital investments.
- Dynamic Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your adjustments.
- Scenario Analysis: Generate various forecasting scenarios to evaluate different valuation results.
- User-Friendly Interface: Intuitive, organized, and crafted for both professionals and newcomers.
How It Works
- Download the Template: Gain immediate access to the Excel-based AUTL DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional parameters.
- Instant Calculations: The model automatically recalculates Autolus Therapeutics' intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the results to inform your investment or financial analysis.
Why Choose This Calculator for Autolus Therapeutics (AUTL)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters easily to suit your financial analysis.
- Real-Time Valuation: Observe immediate updates to Autolus’s valuation as you change the inputs.
- Preloaded Data: Comes equipped with Autolus's actual financial metrics for swift evaluations.
- Relied Upon by Experts: Utilized by investors and analysts for making well-informed choices.
Who Should Use Autolus Therapeutics plc (AUTL)?
- Investors: Gain insights into innovative therapies and make informed investment choices.
- Healthcare Analysts: Utilize comprehensive data to evaluate the potential of cutting-edge treatments.
- Consultants: Tailor reports and presentations quickly using the latest research from Autolus Therapeutics.
- Biotech Enthusiasts: Expand your knowledge of advanced cell therapies and their market impact.
- Educators and Students: Leverage real-world case studies to enhance learning in biotechnology and pharmaceuticals.
What the Template Contains
- Historical Data: Includes Autolus Therapeutics plc’s past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Autolus Therapeutics plc’s intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Autolus Therapeutics plc’s financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.